Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionLPL Financial LLC
Latest Disclosed Ownership67,637 shares
Latest Disclosed Value $ 22,378,889
LPL Financial LLC reports 47.30% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 6, 2026 - LPL Financial LLC filed a 13F-HR form disclosing ownership of 67,637 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $19,323,891 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 45,919 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 47.30% during the quarter. The current value of the position is $17,619,438 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-06 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 67,637 21,718 47.30 22,379 22.56 0.0059
2026-02-11 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 45,919 -2,561 -5.28 18,259 -17.40 0.0050
2025-11-12 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 48,480 18,141 59.79 22,107 123.45 0.0064
2025-08-12 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 30,339 9,660 46.71 9,893 77.20 0.0033
2025-05-07 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 20,679 2,107 11.35 5,584 27.76 0.0022
2025-02-11 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 18,572 -234 -1.24 4,370 -15.51 0.0018
2024-11-08 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 18,806 170 0.91 5,172 14.22 0.0023
2024-08-07 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 18,636 1,662 9.79 4,529 78.55 0.0023
2024-05-10 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,974 253 1.51 2,537 -20.75 0.0014
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,721 951 6.03 3,201 14.61 0.0019
2023-11-13 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,770 895 6.02 2,793 -1.17 0.0020
2023-07-31 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,875 165 1.12 2,825 -4.11 0.0020
2023-05-10 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,710 925 6.71 2,947 -10.07 0.0023
2023-02-07 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,785 547 4.13 3,276 23.62 0.0028
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,238 1,455 12.35 2,650 54.16 0.0026
2022-08-12 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,783 -4,825 -29.05 1,719 -36.62 0.0016
2022-05-16 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,608 714 4.49 2,712 0.63 0.0023
2022-02-14 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,894 2,792 21.31 2,695 8.93 0.0023
2021-11-15 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,102 2,858 27.90 2,474 42.43 0.0023
2021-08-13 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,244 1,143 12.56 1,737 35.18 0.0018
2021-05-14 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,101 3,519 63.04 1,285 77.24 0.0015
2021-02-12 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,582 -98 -1.73 725 -12.33 0.0009
2020-11-09 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,680 360 6.77 827 4.95 0.0013
2020-08-13 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,320 577 12.17 788 52.71 0.0014
2020-05-14 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,743 108 2.33 516 -3.37 0.0011
2020-02-14 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,635 280 6.43 534 52.57 0.0010
2019-11-13 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,355 -874 -16.71 350 -7.65 0.0007
2019-08-09 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,229 857 19.60 379 -7.33 0.0008
2019-05-08 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,372 1,331 43.77 409 84.23 0.0009
2019-02-07 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,041 -892 -22.68 222 -35.47 0.0006
2018-11-14 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,933 176 4.68 344 -7.03 0.0008
2018-08-14 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,757 107 2.93 370 -14.94 0.0010
2018-05-15 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,650 958 35.59 435 27.19 0.0012
2018-02-14 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,692 -126 -4.47 342 3.32 0.0010
2017-11-14 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,818 2,818 331 0.0012
2016-08-15 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -4,098 -100.00 0 -100.00
2016-05-16 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,098 -17,650 -81.16 280 -86.41 0.0008
2016-02-12 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 21,748 10,779 98.27 2,061 134.20 0.0057
2015-11-13 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,969 2,280 26.24 880 -14.65 0.0048
2015-08-14 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,689 115 1.34 1,031 14.30 0.0052
2015-05-14 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,574 560 6.99 902 16.09 0.0046
2015-02-13 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,014 -62 -0.77 777 24.92 0.0043
2014-11-10 2014-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,076 0 0.00 622 21.96 0.0037
2014-08-05 2014-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 8,076 -8,558 -51.45 510 -54.34 0.0030
2014-08-05 2014-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,076 510
2014-05-12 2014-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,634 3,746 29.07 1,117 34.74 0.0069
2014-02-13 2013-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,888 5,369 71.41 829 85.46 0.0052
2013-11-04 2013-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,519 -132 -1.73 447 88.61 0.0030
2013-08-15 2013-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,651 7,651 237 0.0017
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.